Total Payments
$124,378
2024 Payments
$24,740
Companies
13
Transactions
91
Medicare Patients
547
Medicare Billing
$107,183
Payment Breakdown by Category
Other$58,676 (47.2%)
Consulting$57,686 (46.4%)
Research$3,151 (2.5%)
Food & Beverage$2,399 (1.9%)
Travel$2,365 (1.9%)
Education$99.95 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $58,676 | 28 | 47.2% |
| Consulting Fee | $57,686 | 13 | 46.4% |
| Unspecified | $3,151 | 5 | 2.5% |
| Food and Beverage | $2,399 | 26 | 1.9% |
| Travel and Lodging | $2,365 | 18 | 1.9% |
| Education | $99.95 | 1 | 0.1% |
Payments by Type
General
$121,227
86 transactions
Research
$3,151
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Incyte Corporation | $43,522 | 37 | $0 (2024) |
| Foundation Medicine, Inc. | $38,571 | 5 | $0 (2019) |
| Regeneron Pharmaceuticals, Inc. | $12,625 | 18 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $12,068 | 12 | $0 (2024) |
| Genentech USA, Inc. | $5,739 | 5 | $0 (2022) |
| Seagen Inc. | $4,670 | 3 | $0 (2023) |
| E.R. Squibb & Sons, L.L.C. | $4,152 | 1 | $0 (2022) |
| Novartis Pharmaceuticals Corporation | $1,644 | 3 | $0 (2018) |
| Deciphera Pharmaceuticals Inc. | $1,050 | 2 | $0 (2021) |
| Ipsen Bioscience Inc | $103.94 | 1 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,740 | 34 | Regeneron Pharmaceuticals, Inc. ($12,240) |
| 2023 | $18,004 | 18 | Incyte Corporation ($10,085) |
| 2022 | $14,767 | 12 | Incyte Corporation ($7,795) |
| 2021 | $18,970 | 14 | Incyte Corporation ($12,157) |
| 2020 | $7,480 | 3 | Incyte Corporation ($7,380) |
| 2019 | $12,952 | 3 | Foundation Medicine, Inc. ($12,750) |
| 2018 | $27,464 | 7 | Foundation Medicine, Inc. ($25,821) |
All Payment Transactions
91 individual payment records from CMS Open Payments — Page 1 of 4
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/12/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Oncology | ||||||
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Oncology | ||||||
| 10/23/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $17.56 | General |
| Category: ENDOCRINOLOGY | ||||||
| 10/22/2024 | Incyte Corporation | PEMAZYRE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,740.00 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 10/16/2024 | Incyte Corporation | PEMAZYRE (Drug) | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 10/16/2024 | Incyte Corporation | PEMAZYRE (Drug) | Travel and Lodging | Cash or cash equivalent | $16.75 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 09/09/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $309.08 | Research |
| Study: A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS • Category: ONCOLOGY | ||||||
| 08/21/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,350.00 | General |
| Category: Oncology | ||||||
| 08/02/2024 | Regeneron Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,672.00 | General |
| 08/02/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $575.26 | General |
| 08/02/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $27.59 | General |
| 08/02/2024 | Regeneron Pharmaceuticals, Inc. | — | Travel and Lodging | In-kind items and services | $22.00 | General |
| 06/24/2024 | ABBVIE INC. | CREON (Drug) | Food and Beverage | In-kind items and services | $17.23 | General |
| Category: ENDOCRINOLOGY | ||||||
| 06/05/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $76.42 | General |
| 06/05/2024 | Regeneron Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $31.97 | General |
| 05/07/2024 | Incyte Corporation | PEMAZYRE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,740.00 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 05/01/2024 | Incyte Corporation | PEMAZYRE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $342.50 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 05/01/2024 | Incyte Corporation | PEMAZYRE (Drug) | Food and Beverage | Cash or cash equivalent | $121.41 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 05/01/2024 | Incyte Corporation | PEMAZYRE (Drug) | Travel and Lodging | Cash or cash equivalent | $13.40 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 05/01/2024 | Incyte Corporation | PEMAZYRE (Drug) | Travel and Lodging | Cash or cash equivalent | $5.00 | General |
| Category: Hepatology (Liver, Pancreatic, Gall Bladder) | ||||||
| 04/25/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,100.00 | General |
| Category: Oncology | ||||||
| 04/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Food and Beverage | In-kind items and services | $123.06 | General |
| Category: Oncology | ||||||
| 04/22/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Travel and Lodging | In-kind items and services | $53.60 | General |
| Category: Oncology | ||||||
| 03/29/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $268.62 | Research |
| Study: A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS • Category: ONCOLOGY | ||||||
| 03/20/2024 | Regeneron Pharmaceuticals, Inc. | LIBTAYO (Biological) | — | In-kind items and services | $737.09 | Research |
| Study: A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS • Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 1/2 STUDY OF REGN7075 (EGFRXCD28 COSTIMULATORY BISPECIFIC ANTIBODY) IN COMBINATION WITH CEMIPLIMAB IN PATIENTS WITH ADVANCED SOLID TUMORS | Regeneron Pharmaceuticals, Inc. | $1,701 | 4 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $1,450 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 133 | 280 | $96,828 | $28,488 |
| 2022 | 4 | 138 | 249 | $77,295 | $24,593 |
| 2021 | 6 | 156 | 288 | $80,389 | $30,628 |
| 2020 | 4 | 120 | 236 | $74,843 | $23,474 |
Total Patients
547
Total Services
1,053
Medicare Billing
$107,183
Procedure Codes
18
All Medicare Procedures & Services
18 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 54 | 188 | $65,800 | $19,584 | 29.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 38 | 38 | $16,796 | $5,284 | 31.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 27 | 39 | $11,817 | $2,918 | 24.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 14 | 15 | $2,415 | $702.00 | 29.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 53 | 146 | $45,552 | $15,405 | 33.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 50 | 50 | $21,350 | $6,214 | 29.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 21 | 37 | $8,069 | $2,267 | 28.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 14 | 16 | $2,324 | $708.10 | 30.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 49 | 157 | $43,018 | $17,543 | 40.8% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 32 | 32 | $13,344 | $4,602 | 34.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 29 | 46 | $8,878 | $3,565 | 40.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 16 | 16 | $8,016 | $2,395 | 29.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 14 | 19 | $4,883 | $1,580 | 32.3% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 16 | 18 | $2,250 | $943.25 | 41.9% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 51 | 151 | $41,374 | $12,715 | 30.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 33 | 33 | $13,761 | $4,297 | 31.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 22 | 26 | $13,026 | $4,267 | 32.8% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 14 | 26 | $6,682 | $2,195 | 32.8% |
About Davendra Sohal, MD, MPH
Davendra Sohal, MD, MPH is a Hematology & Oncology healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2008. The National Provider Identifier (NPI) number assigned to this provider is 1083877914.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Davendra Sohal, MD, MPH has received a total of $124,378 in payments from pharmaceutical and medical device companies, with $24,740 received in 2024. These payments were reported across 91 transactions from 13 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($58,676).
As a Medicare-enrolled provider, Sohal has provided services to 547 Medicare beneficiaries, totaling 1,053 services with total Medicare billing of $107,183. Data is available for 4 years (2020–2023), covering 18 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Cincinnati, OH
- Active Since 07/10/2008
- Last Updated 05/13/2020
- Taxonomy Code 207RH0003X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1083877914
Products in Payments
- PEMAZYRE (Drug) $38,602
- FOUNDATIONONE LIQUID (Device) $38,571
- IMFINZI (Biological) $11,829
- TECENTRIQ (Biological) $5,739
- JAKAFI (Drug) $4,920
- TUKYSA (Drug) $4,670
- KISQALI (Drug) $1,450
- LIBTAYO (Biological) $1,315
- QINLOCK (Drug) $1,050
- ENTRESTO (Drug) $193.70
- LYNPARZA (Drug) $103.96
- ONIVYDE (Drug) $103.94
- Vectibix (Biological) $97.87
- CREON (Drug) $34.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Cincinnati
Dr. David Waterhouse, Md, MD
Hematology & Oncology — Payments: $1.3M
Hematology & Oncology $1.3M
Dr. Elyse Lower, Md, MD
Hematology & Oncology — Payments: $386,700
Hematology & Oncology $386,700
Dr. Alexander Starodub, Md, Phd, MD, PHD
Hematology & Oncology — Payments: $254,325
Hematology & Oncology $254,325
Dr. James Essell, Md, MD
Hematology & Oncology — Payments: $223,019
Hematology & Oncology $223,019
Dr. Edward Faber, D.o., M.s, D.O., M.S
Hematology & Oncology — Payments: $116,895
Hematology & Oncology $116,895
Dr. Soumit Basu, M.d. Ph.d, M.D. PH.D
Hematology & Oncology — Payments: $114,168
Hematology & Oncology $114,168